Susanna Naggie, MD

Professor of Medicine
Vice Dean for Clinical Research
Member in the Duke Clinical Research Institute
Campus mail 300 West Morgan St, Suite 800, Durham, NC 27701
Phone (919) 684-2584
Email address susanna.naggie@duke.edu

Dr. Susanna Naggie completed her medical education at Johns Hopkins School of Medicine and her internal medicine training at Duke University Medical Center (DUMC), where she also served as a Chief Resident in Internal Medicine.  She completed her Infectious Diseases (ID) fellowship training at Duke and then joined the faculty in the Division of ID. She is an Associate Professor of Medicine with Tenure and currently holds joint appointments at the Duke Clinical Research Institute (DCRI, Director of ID Research), and at the Durham Veterans Affairs Medical Center (DVAMC). Dr. Naggie has dedicated her academic career to the care of patients with HIV and viral hepatitis, with a research program focused on understanding the mechanisms of accelerated liver fibrogenesis in this population and the extrahepatic health outcomes attributed to HCV in persons with HIV infection. In addition to her investigator-initiated research program, Dr. Naggie is also involved in multiple clinical trials and clinical registries with a particular focus on HIV and liver disease. She is the prior co-Chair of the AASLD/IDSA HCV Guidance Committee and is currently Chair of the AIDS Clinical Trials Group Viral Hepatitis Transformative Science Group Committee and a member of the DHHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV and the CDC/NIH/IDSA-HIVMA Opportunistic Infections Guideline Committee. For the past two years Dr. Naggie has served as the Medical Director of the Duke Department of Medicine Clinical Research Unit.

Education and Training

  • Fellow in Infectious Diseases, Medicine, Duke University, 2007 - 2009
  • Chief Medical Resident - VAMC, Medicine, Duke University, 2006 - 2007
  • Medical Resident, Medicine, Duke University, 2002 - 2005
  • M.D., Johns Hopkins University, 2002

Publications

Clark, P. J., A. J. Thompson, H. L. Tillmann, A. Jazwinski, S. Naggie, A. J. Muir, and K. Patel. “884 EXPLORATION OF SERUM ADIPOCYTOKINE ASSOCIATIONS WITH IL28B GENOTYPE IN CHRONIC HEPATITIS C.” In Journal of Hepatology, 56:S344–S344. Elsevier BV, 2012. https://doi.org/10.1016/s0168-8278(12)60896-4.

Full Text

Naggie, Susanna, Norma I. Rallon, José M. Benito, Judith Morello, Sonia Rodriguez-Novoa, Paul J. Clark, Alexander J. Thompson, et al. “Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes.” J Infect Dis 205, no. 3 (February 1, 2012): 376–83. https://doi.org/10.1093/infdis/jir754.

PMID
22158703
Full Text

Thompson, Alexander J., Paul J. Clark, Abanish Singh, Dongliang Ge, Jacques Fellay, Mingfu Zhu, Qianqian Zhu, et al. “Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients.” J Hepatol 56, no. 2 (February 2012): 313–19. https://doi.org/10.1016/j.jhep.2011.04.021.

PMID
21703177
Full Text

Osinusi, A., and S. Naggie. “The role of IL28B genotype testing in the era of direct acting antiviral agents.” European Gastroenterology and Hepatology Review 8, no. 1 (January 1, 2012): 33–39.

Scholars@Duke

Osinusi, Anu, and Susanna Naggie. “The Role of IL28B Genotype Testing in the Era of Direct Acting Antiviral Agents.” Eur Gastroenterol Hepatol Rev 1, no. 2 (2012): 33–39.

PMID
24639890
Scholars@Duke

Goswami, Neela D., Emily J. Hecker, Carter Vickery, Marshall A. Ahearn, Gary M. Cox, David P. Holland, Susanna Naggie, et al. “Geographic information system-based screening for TB, HIV, and syphilis (GIS-THIS): a cross-sectional study.” Plos One 7, no. 10 (2012): e46029. https://doi.org/10.1371/journal.pone.0046029.

PMID
23056227
Full Text

Goswami, Neela D., Emily Hecker, David P. Holland, Susanna Naggie, Gary M. Cox, Ann Mosher, Debbie Turner, et al. “Feasibility and willingness-to-pay for integrated community-based tuberculosis testing.” Bmc Infect Dis 11 (November 2, 2011): 305. https://doi.org/10.1186/1471-2334-11-305.

PMID
22047015
Full Text

Clark, Paul J., Alexander J. Thompson, Thomas J. Urban, Keyur Patel, David M. Vock, Qianqian Zhu, Alison Jazwinski, et al. “PNPLA3 GENOTYPE RATHER THAN RACE MAY EXPLAIN THE LOWER PREVALENCE OF HEPATIC STEATOSIS DESPITE WORSE METABOLIC RISK FACTORS IN AFRICAN AMERICAN PATIENTS WITH CHRONIC HEPATITIS C (CHC).” In Hepatology, 54:402A-402A. WILEY-BLACKWELL, 2011.

Scholars@Duke

Thompson, Alexander J., Paul J. Clark, Hans L. Tillmann, Keyur Patel, Susanna Naggie, F Fred Poordad, Eric Lawitz, et al. “= 1 LOG10 IU/ML REDUCTION IN PLASMA HCV RNA AFTER 4 WEEKS OF PEGINTERFERON (PEGIFN) AND RIBAVIRIN (RBV) THERAPY: IMPLICATIONS FOR THE USE OF THE LEAD-IN STRATEGY FOR DIRECT-ACTING ANTIVIRAL-BASED TREATMENT REGIMENS.” In Hepatology, 54:436A-437A. WILEY-BLACKWELL, 2011.

Scholars@Duke

Thompson, Alexander J., Paul J. Clark, David M. Vock, Ruth Pfeiffer, Hans L. Tillmann, Keyur Patel, Susanna Naggie, et al. “PREDICTING PEGINTERFERON-alpha AND RIBAVIRIN TREATMENT RESPONSE IN GENOTYPE 1 HCV PATIENTS - SIMPLE NOMOGRAMS TO SUPPORT CLINICIANS.” In Hepatology, 54:803A-804A. WILEY-BLACKWELL, 2011.

Scholars@Duke

Pages